June 2022
Volume 63, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2022
Ophthalmic Biopharmaceutics Classification System (oBCS): in vitro in silico relationship (IVISR) for comparability risk assessment in topical eye drop formulations
Author Affiliations & Notes
  • Hovhannes John Gukasyan
    Pharmacology and Pharmaceutical Sciences, University of Southern California, Los Angeles, California, United States
  • Xavier Faraj
    University of Southern California, Los Angeles, California, United States
  • Melissa Martinez
    University of Southern California, Los Angeles, California, United States
  • Ian S Haworth
    Pharmacology and Pharmaceutical Sciences, University of Southern California, Los Angeles, California, United States
  • Footnotes
    Commercial Relationships   Hovhannes Gukasyan None; Xavier Faraj None; Melissa Martinez None; Ian S Haworth None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2022, Vol.63, 4169 – F0161. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Hovhannes John Gukasyan, Xavier Faraj, Melissa Martinez, Ian S Haworth; Ophthalmic Biopharmaceutics Classification System (oBCS): in vitro in silico relationship (IVISR) for comparability risk assessment in topical eye drop formulations. Invest. Ophthalmol. Vis. Sci. 2022;63(7):4169 – F0161.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Perform composite parameter sensitivity analysis, elucidate relative contribution of two parallel drug penetration pathways into eye from topically applied drops, towards establishing an oBCS and refining its framework.

Methods : Experimentally determined intrinsic solubility values of drug substances found in commercially available eye drops were compiled. A subset of forty drugs with available in vitro corneal (Cr) and conjunctival (Cj) tissue permeability (Papp) data, expressed as CrPapp/CjPapp, were used to plot sensitivity surfaces as a function of total topical ophthalmic dose (Do). Extent of aqueous humor (AqH), iris-ciliary body (ICB) and systemic exposure was calculated 0-20 minutes (e.g. AUC0-20min) using OCAT™ simulated topical ophthalmic dosing as a function of corneal vs. conjunctival penetration access, and nasolacrimal drainage. Do and CrPapp/CjPapp parameter sensitivity analysis (PSA) were performed on 40 drugs to assess influence of corneal/conjunctival permeability, dose/solubility ratios on extent of absorption into eye vs. systemic.

Results : Contribution of the corneal route of absorption was dominant at nearly 90% fraction of dose reaching AqH for all compounds, while relatively low corneal permeability ones displayed up to 90% dependence of their ICB exposure on conjunctival access. Similarly, Do displayed up to 40% dependence on ICB access via conjunctival absorption, however was insensitive towards AqH access via corneal route of penetration. Contribution of nasolacrimal drainage towards systemic exposure displayed up to 15% dependence specifically on compounds with corneal penetration route preference as a function of increasing Do, while the opposite was true for compounds with conjunctival penetration route preference.

Conclusions : A oBCS is proposed in FIGURE. Pragmatic limitations in ocular bioanalysis result in challenges for bioequivalence establishment between different topical ophthalmic formulations of the same drug substance. There is potential value for computational model integrated biopharmaceutics in formulation design, optimization, and performance prediction.

This abstract was presented at the 2022 ARVO Annual Meeting, held in Denver, CO, May 1-4, 2022, and virtually.

 

Parameter Sensitivity Analysis Plots

Parameter Sensitivity Analysis Plots

 

Ophthalmic Biopharmaceutics Classification System (oBCS)

Ophthalmic Biopharmaceutics Classification System (oBCS)

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×